Autoimmune Disorders: The Next Frontier for CAR-T Therapies

Scientists and clinicians have harnessed CAR-T’s power against hematological malignancies, and continued research focuses on solid tumors.

So, what’s next?

It appears autoimmunity is the next step in the expansion of CAR-T cell therapies outside of oncology. This is highlighted by 43 active gene-modified cell therapy clinical trials targeting autoimmune disorders, 3 of which are phase III trials located in the US.

Click the PDF below to learn more about this space and stay informed on the latest cell and gene therapy trends.